Skip to main content
Midas Edge

CRESCENT BIOPHARMA, INC.

For the period ended Jul 29, 2025. Filed Jul 31, 2025.

View on SEC.gov

About this filing

A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.

Jul 29, 2025 · Filed Jul 31, 2025

Use the contents to explore the available documents and sections.

CBIO$13.54+4.6%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

EX-99.1 · Reference:

Reference:

  1. Xiong, Anwen et al. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. The Lancet, 2025; 405(10481): 839-849.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.